BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 17505264)

  • 21. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
    Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
    Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
    Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
    J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
    Auroy S; Avril MF; Chompret A; Pham D; Goldstein AM; Bianchi-Scarrà G; Frebourg T; Joly P; Spatz A; Rubino C; Demenais F; Bressac-de Paillerets B;
    Genes Chromosomes Cancer; 2001 Nov; 32(3):195-202. PubMed ID: 11579459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds.
    Lang JM; Shennan M; Njauw JC; Luo S; Bishop JN; Harland M; Hayward NK; Tucker MA; Goldstein AM; Landi MT; Puig S; Gruis NA; Bergman W; Bianchi-Scarra G; Ghiorzo P; Hogg D; Tsao H
    J Invest Dermatol; 2011 Feb; 131(2):480-6. PubMed ID: 21085193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.
    Sargen MR; Pfeiffer RM; Yang XR; Tucker MA; Goldstein AM
    J Invest Dermatol; 2020 Jan; 140(1):174-181.e3. PubMed ID: 31326397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The CDKN2a common variants: 148 Ala/Thr and 500 C/G in 3' UTR, and their association with clinical course of melanoma.
    Lamperska KM; Przybyła A; Kycler W; Mackiewicz A
    Acta Biochim Pol; 2007; 54(1):119-24. PubMed ID: 17351674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
    Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
    Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele.
    Bertram CG; Gaut RM; Barrett JH; Pinney E; Whitaker L; Turner F; Bataille V; Dos Santos Silva I; J Swerdlow A; Bishop DT; Newton Bishop JA
    J Invest Dermatol; 2002 Oct; 119(4):961-5. PubMed ID: 12406345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
    Karagianni F; Njauw CN; Kypreou KP; Stergiopoulou A; Plaka M; Polydorou D; Chasapi V; Pappas L; Stratigos IA; Champsas G; Panagiotou P; Gogas H; Evangelou E; Tsao H; Stratigos AJ; Stefanaki I
    Acta Derm Venereol; 2018 Oct; 98(9):862-866. PubMed ID: 29774366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma.
    Stratigos AJ; Yang G; Dimisianos R; Nicolaou V; Stefanaki I; Katsambas AD; Tsao H
    J Invest Dermatol; 2006 Feb; 126(2):399-401. PubMed ID: 16374456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The lack of E318K MITF germline mutation in Latvian melanoma patients.
    Ozola A; Pjanova D
    Cancer Genet; 2015 Jun; 208(6):355-6. PubMed ID: 25975176
    [No Abstract]   [Full Text] [Related]  

  • 35. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
    Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
    Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
    Potjer TP; Bollen S; Grimbergen AJEM; van Doorn R; Gruis NA; van Asperen CJ; Hes FJ; van der Stoep N;
    Int J Cancer; 2019 May; 144(10):2453-2464. PubMed ID: 30414346
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Tovar-Parra JD; Gutiérrez-Castañeda LD; Gil-Quiñones SR; Nova JA; Pulido L
    Biomed Res Int; 2020; 2020():7458917. PubMed ID: 33102592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDKN2A mutations in melanoma families from Uruguay.
    Larre Borges A; Cuéllar F; Puig-Butillé JA; Scarone M; Delgado L; Badenas C; Milà M; Malvehy J; Barquet V; Núñez J; Laporte M; Fernández G; Levrero P; Martínez-Asuaga M; Puig S
    Br J Dermatol; 2009 Sep; 161(3):536-41. PubMed ID: 19523171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical histopathological features and CDKN2A/CDK4/MITF mutational status of patients with multiple primary melanomas from Bologna: Italy is a fascinating but complex mosaic.
    Dika E; Patrizi A; Rossi C; Turchetti D; Miccoli S; Ferracin M; Veronesi G; Scarfì F; Lambertini M
    Ital J Dermatol Venerol; 2021 Oct; 156(5):599-605. PubMed ID: 32221274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
    Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
    Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.